Catalent gets grant, joins effort to improve vaccine properties

Catalent receives vaccine-research grant.
Catalent receives vaccine-research grant. | Courtesy of

Catalent -- a global provider of advanced delivery technologies, as well as development solutions, for biologics, drugs and consumer health products -- recently said it has accepted a grant as part of a consortium to fund the research, development and production of thermo-stable and cold-chain independent nano-pharmaceutical virosome-based vaccine candidates.

As of today, 90 percent of the vaccines currently in use depend on cold chains. The goal of the consortium and the grant is to create a scalable manufacturing process dedicated to making vaccines stable and temperature-independent.

The grant -- worth more than $5 million -- is part of Horizon 2020, the research and innovation framework program with the European Union. Additional funding amounting to more than $3 million will be made available for the consortium partners based in Switzerland from the Swiss State Secretariat Education, Research and Innovation (SERI).

“Catalent is pleased to be part of this consortium of cross-industry partners bringing innovative technologies together to address a serious global issue in the over-reliance on the cold chain with existing vaccines,” Barry Littlejohns, Catalent’s president of advanced delivery technologies, said. “Zydis is the world’s best-in-class, orally disintegrating tablet technology, and we believe our experience and expertise in this area can add substantially to the project as a whole. Because of the supply-chain constraints, large populations are denied access to vaccines, so we, as a group, recognize the importance and potential of this work for global vaccine development.”

Organizations in this Story

Catalent Pharma Solutions Swiss State Secretariat Education, Research and Innovation

Want to get notified whenever we write about any of these organizations ?
Next time we write about any of these organizations, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.